Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 33521954 | HLA MATCHED (HLA-MATCHED) | hematopoietic stem cell transplantation | NA | NA | NA | unclassified | |
| we retrospectively analysed the data of 30 aya patients (19 in first complete remission [cr1], 3 in cr2, and 8 with active disease) with etp-all who underwent myeloablative allogeneic hematopoietic stem cell transplantation (allo-hsct) from hla-matched related, n = 2, unrelated, n = 5, or hla-haploidentical related, n = 23 donors with an emphasis on the impact of disease status on the outcomes of transplant. | |||||||
| 33674791 | HLA MISMATCHED (HLA-MISMATCHED) | hematopoietic stem cell transplantation | NA | cyclophosphamide | NA | unclassified | |
| the barriers to hla-mismatched or haploidentical hematopoietic stem cell transplantation (hsct), namely gvhd and graft failure, have been overcome with novel transplant platforms. | |||||||
| 33736934 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | hematopoietic stem cell transplantation | NA | NA | NA | unclassified | |
| aimstotal nucleated cell (tnc) and cd34+ cell doses are considered among the most important parameters when assessing the suitability of a human leukocyte antigen-matched cord blood unit (cbu) for allogeneic hematopoietic stem cell transplantation (hsct). | |||||||
| 33781751 | HLA MATCHED (HLA-MATCHED) | hematopoietic stem cell transplantation | Saudi Arabian | NA | NA | unclassified | |
| finding hla-matched donors for patients in need of hematopoietic stem cell transplantation (hsct) stands a better chance in their own ethnic group. | |||||||
| 33796400 | HLA IDENTICAL (HLA-IDENTICAL) | lenalidomide | NA | melphalan | NA | unclassified | |
| NA | |||||||
| 33936051 | HLA-DPB1 (HLA-DPB1) | hematopoietic stem cell transplantation | Chinese | NA | NA | unclassified | |
| high resolution typing of the hla-dpb1 locus for patient who requested for hematopoietic stem cell transplantation (hsct) workup has recently become mandatory by the national marrow donor program (nmdp) in order to facilitate matching between donors and recipients for better outcomes. | |||||||
| 34001105 | DP (HAPLOTYPE) | idarubicin | NA | cytarabine | NA | unclassified | |
| NA | |||||||
| 34116583 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | hematopoietic stem cell transplantation | NA | NA | NA | unclassified | |
| both patients underwent hematopoietic stem cell transplantation from human leukocyte antigen-matched family member. | |||||||
| 34120595 | HLA MATCHED (HLA-MATCHED) | hematopoietic stem cell transplantation | NA | NA | NA | only_studied | |
| a sequential allogeneic hla-matched sible hematopoietic stem cell transplantation (allo-hsct) was carried out, and the donor is the patient's elder brother, the original two variants of patient were replaced by the donor-derived tet2 (p.asp1844asn) variant after allo-hsct; the patient has remained in complete remission with regular follow-up. | |||||||
| 34320787 | HLA MATCHED (HLA-MATCHED) | hematopoietic stem cell transplantation | NA | NA | NA | unclassified | |
| allogeneic hematopoietic stem cell transplantation from nonsibling 10/10 hla-matched related donors: a single-center experience. | |||||||
Copyright 2024